Skip to main content
Premium Trial:

Request an Annual Quote

Dennis Gilbert, Frank Douglas, Janet Lankard, Nicolas Roelofs, Joseph Sorge

Premium

Dennis Gilbert has become CSO and vice president for research of Applied Biosystems, as well as vice president of Applera, the company said in an SEC filing last week. He joined Applera in 1994 as a research scientist and was most recently ABI’s vice president for advanced research and technology.


Frank Douglas has been appointed to fill a vacancy on the board of directors of Gene Logic with a term ending at the next annual stockholders meeting, at that time, he will be considered for election for a full term. Douglas recently retired from Aventis, where he served as executive vice president of drug innovation and approval and CSO.


Quantum Dot said last week that Janet Lankard has been named vice president of sales, and will lead the sales team for Quantum Dot’s upcoming launch of the Mosaic gene expression assay system. Lankard formerly was a director of sales for Affymetrix, which she joined in 1998. She has also been an executive sales account manager with Applied Biosystems, and was responsible for the Joint Genome Institute during the Human Genome Sequencing project. She serves on the Industrial Advisory Board for California Polytechnic State University. Lankard holds a BA in biochemistry from Cal Poly San Luis Obispo.


Nicolas Roelofs has resigned his position as COO of Stratagene effective Dec. 31. The resignation was disclosed in an SEC filing last week. Stratagene said Roelofs was leaving the firm to spend more time with his family. The company said it would search for a replacement upon his departure, and in the meantime CEO Joseph Sorge would assume Roelofs’ responsibilities.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.